Search research articles
Contact Us
Filters
Showing results (421-430 of 481) with videos related to
Page
of 49
Sort By:
The Journal of Physiology
|
July 15, 2022
Oral digoxin effects on exercise performance, K<sup>+</sup> regulation and skeletal muscle Na<sup>+</sup> ,K<sup>+</sup> -ATPase in healthy humans
Simon Sostaric, Aaron C Petersen, Craig A Goodman, et al.
Health Technology Assessment (Winchester, England)
|
May 12, 2026
Mammographic surveillance in breast cancer patients aged 50 years or older: a synopsis of the Mammo-50 RCT
Janet Dunn, Peter Donnelly, Andrea Marshall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 12, 2010
Breast cancer in pregnancy: recommendations of an international consensus meeting
Frédéric Amant, Sarah Deckers, Kristel Van Calsteren, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 12, 2022
The Kynurenine Pathway Metabolites in Cord Blood Positively Correlate With Early Childhood Adiposity
Karen Mei-Ling Tan, Mya-Thway Tint, Narasimhan Kothandaraman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
Richard D Gelber, Xin V Wang, Bernard F Cole, et al.
The Lancet. Oncology
|
September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
Angelo Di Leo, Christine Desmedt, John M S Bartlett, et al.
Virchows Archiv : an International Journal of Pathology
|
October 19, 2023
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
Charo Garrido, Melissa Manoogian, Dhiraj Ghambire, et al.
Breast Cancer Research and Treatment
|
February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Andrew Wardley, Javier Cortes, Louise Provencher, et al.
The Lancet. Oncology
|
August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
Stephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.
Lancet (London, England)
|
May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Paul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.
Page
of 49
Search research articles
Search
Showing results (421-430 of 481) with videos related to
Sort By:
Page
of 49
The Journal of Physiology
|
July 15, 2022
Oral digoxin effects on exercise performance, K<sup>+</sup> regulation and skeletal muscle Na<sup>+</sup> ,K<sup>+</sup> -ATPase in healthy humans
Simon Sostaric, Aaron C Petersen, Craig A Goodman, et al.
Health Technology Assessment (Winchester, England)
|
May 12, 2026
Mammographic surveillance in breast cancer patients aged 50 years or older: a synopsis of the Mammo-50 RCT
Janet Dunn, Peter Donnelly, Andrea Marshall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 12, 2010
Breast cancer in pregnancy: recommendations of an international consensus meeting
Frédéric Amant, Sarah Deckers, Kristel Van Calsteren, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 12, 2022
The Kynurenine Pathway Metabolites in Cord Blood Positively Correlate With Early Childhood Adiposity
Karen Mei-Ling Tan, Mya-Thway Tint, Narasimhan Kothandaraman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
Richard D Gelber, Xin V Wang, Bernard F Cole, et al.
The Lancet. Oncology
|
September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
Angelo Di Leo, Christine Desmedt, John M S Bartlett, et al.
Virchows Archiv : an International Journal of Pathology
|
October 19, 2023
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
Charo Garrido, Melissa Manoogian, Dhiraj Ghambire, et al.
Breast Cancer Research and Treatment
|
February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Andrew Wardley, Javier Cortes, Louise Provencher, et al.
The Lancet. Oncology
|
August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
Stephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.
Lancet (London, England)
|
May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Paul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.
Page
of 49